Literature DB >> 28060251

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis.

Sung-Hyeok Hong1, Jason U Tilan2, Susana Galli1, Rachel Acree3, Katherine Connors4, Akanksha Mahajan1, Larissa Wietlisbach3, Taylor Polk3, Ewa Izycka-Swieszewska5, Yi-Chien Lee6, Luciane R Cavalli6, Olga C Rodriguez6, Chris Albanese7, Joanna B Kitlinska8.   

Abstract

Hypoxia has been implicated in the metastasis of Ewing sarcoma (ES) by clinical observations and in vitro data, yet direct evidence for its pro-metastatic effect is lacking and the exact mechanisms of its action are unclear. Here, we report an animal model that allows for direct testing of the effects of tumor hypoxia on ES dissemination and investigation into the underlying pathways involved. This approach combines two well-established experimental strategies, orthotopic xenografting of ES cells and femoral artery ligation (FAL), which induces hindlimb ischemia. Human ES cells were injected into the gastrocnemius muscles of SCID/beige mice and the primary tumors were allowed to grow to a size of 250 mm3. At this stage either the tumors were excised (control group) or the animals were subjected to FAL to create tumor hypoxia, followed by tumor excision 3 days later. The efficiency of FAL was confirmed by a significant increase in binding of hypoxyprobe-1 in the tumor tissue, severe tumor necrosis and complete inhibition of primary tumor growth. Importantly, despite these direct effects of ischemia, an enhanced dissemination of tumor cells from the hypoxic tumors was observed. This experimental strategy enables comparative analysis of the metastatic properties of primary tumors of the same size, yet significantly different levels of hypoxia. It also provides a new platform to further assess the mechanistic basis for the hypoxia-induced alterations that occur during metastatic tumor progression in vivo. In addition, while this model was established using ES cells, we anticipate that this experimental strategy can be used to test the effect of hypoxia in other sarcomas, as well as tumors orthotopically implanted in sites with a well-defined blood supply route.

Entities:  

Mesh:

Year:  2016        PMID: 28060251      PMCID: PMC5222526          DOI: 10.3791/54532

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  27 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

2.  Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's sarcoma cells in vitro.

Authors:  Dave N T Aryee; Stephan Niedan; Maximilian Kauer; Raphaela Schwentner; Idriss M Bennani-Baiti; Jozef Ban; Karin Muehlbacher; Michael Kreppel; Robert L Walker; Paul Meltzer; Christopher Poremba; Reinhard Kofler; Heinrich Kovar
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

3.  Inhibiting platelet-derived growth factor beta reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model.

Authors:  Yong Xin Wang; Deendayal Mandal; Suizhau Wang; Dennis Hughes; Raphael E Pollock; Dina Lev; Eugenie Kleinerman; Andrea Hayes-Jordan
Journal:  In Vivo       Date:  2009 Nov-Dec       Impact factor: 2.155

4.  Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD/scid mice.

Authors:  J Vormoor; G Baersch; S Decker; M Hotfilder; K L Schäfer; L Pelken; C Rübe; F Van Valen; H Jürgens; B Dockhorn-Dworniczak
Journal:  Pediatr Res       Date:  2001-03       Impact factor: 3.756

5.  Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.

Authors:  Maria C Manara; Lorena Landuzzi; Patrizia Nanni; Giordano Nicoletti; Diana Zambelli; Pier Luigi Lollini; Cristina Nanni; Francesco Hofmann; Carlos García-Echeverría; Piero Picci; Katia Scotlandi
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

6.  DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma.

Authors:  Kristina Hauer; Julia Calzada-Wack; Katja Steiger; Thomas G P Grunewald; Daniel Baumhoer; Stephanie Plehm; Thorsten Buch; Olivia Prazeres da Costa; Irene Esposito; Stefan Burdach; Günther H S Richter
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

7.  Establishment of primary cell cultures: experiences with 155 cell strains.

Authors:  M Dietel; H Arps; D Gerding; M Trapp; A Niendorf
Journal:  Klin Wochenschr       Date:  1987-06-01

8.  Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma.

Authors:  Melinda S Merchant; Xuezhong Yang; Fraia Melchionda; Maria Romero; Ruth Klein; Carol J Thiele; Maria Tsokos; H Udo Kontny; Crystal L Mackall
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

9.  Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model.

Authors:  Christiane Franzius; Marc Hotfilder; Christopher Poremba; Sven Hermann; Klaus Schäfers; Helmut Erich Gabbert; Heribert Jürgens; Otmar Schober; Michael Schäfers; Josef Vormoor
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-29       Impact factor: 10.057

10.  Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor.

Authors:  Helen J Knowles; Karl-Ludwig Schaefer; Uta Dirksen; Nicholas A Athanasou
Journal:  BMC Cancer       Date:  2010-07-16       Impact factor: 4.430

View more
  4 in total

1.  Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma.

Authors:  Congyi Lu; Akanksha Mahajan; Sung-Hyeok Hong; Susana Galli; Shiya Zhu; Jason U Tilan; Nouran Abualsaud; Mina Adnani; Stacey Chung; Nada Elmansy; Jasmine Rodgers; Olga Rodriguez; Christopher Albanese; Hongkun Wang; Maureen Regan; Valerie Zgonc; Jan Blancato; Ewa Krawczyk; G Ian Gallicano; Michael Girgis; Amrita Cheema; Ewa Iżycka-Świeszewska; Luciane R Cavalli; Svetlana D Pack; Joanna Kitlinska
Journal:  Nat Commun       Date:  2022-04-28       Impact factor: 17.694

2.  A targeted combinatorial therapy for Ewing's sarcoma.

Authors:  Fahad Y Sabei; Olena Taratula; Hassan A Albarqi; Adel M Al-Fatease; Abraham S Moses; Ananiya A Demessie; Youngrong Park; Walter K Vogel; Ellie Esfandiari Nazzaro; Monika A Davare; Adam Alani; Mark Leid; Oleh Taratula
Journal:  Nanomedicine       Date:  2021-07-23       Impact factor: 6.096

Review 3.  Technical Feasibility and Physiological Relevance of Hypoxic Cell Culture Models.

Authors:  Jiri Pavlacky; Jan Polak
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-21       Impact factor: 5.555

Review 4.  The antitumor mechanisms of aerobic exercise: A review of recent preclinical studies.

Authors:  Ningxin Jia; Yanan Zhou; Xiaosheng Dong; Meng Ding
Journal:  Cancer Med       Date:  2021-08-13       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.